Premium
Expression of the tumor‐rejection antigen SART1 in brain tumors
Author(s) -
Imaizumi Toshihiro,
Kuramoto Terukazu,
Matsunaga Kazuko,
Shichijo Shigeki,
Yutani Shigeru,
Shigemori Minoru,
Oizumi Koutaro,
Itoh Kyogo
Publication year - 1999
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19991210)83:6<760::aid-ijc11>3.0.co;2-r
Subject(s) - antigen , glioma , immunotherapy , cytotoxic t cell , epitope , human leukocyte antigen , immunology , tumor antigen , cancer research , brain tumor , cancer , biology , pathology , medicine , immune system , in vitro , biochemistry
We have reported a tumor‐rejection antigen, SART1 259 , possessing tumor epitopes capable of inducing cytotoxic T lymphocytes (CTLs) in epithelial‐cancer patients. This study investigated the expression of SART1 259 antigen in brain tumors, to explore for a potential molecule for use in specific immunotherapy of patients with brain tumors. The SART1 259 antigen was detected in the cytosol fraction of 13 of 18 (72%) glioma cell lines and in 12 of 34 (35%) brain‐tumor tissues, with a higher rate of expression among malignant gliomas (5/10, 50%) and schwannomas (3/4). HLA‐A24‐restricted and SART1‐specific CTLs recognized the HLA‐A24 + and SART1 259 + glioma cells, and the levels of recognition correlated both with HLA‐A24‐antigen expression level and with the concentration of the SART1 peptide antigen. Therefore, the SART1 259 antigen could be a target molecule for specific immunotherapy of patients with brain tumors expressing HLA‐class‐I antigens. Int. J. Cancer 83:760–764, 1999. © 1999 Wiley‐Liss, Inc.